Horizon Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Horizon Therapeutics wird ein Gewinn- und Umsatzwachstum von 24.9% bzw. 8.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 23.3% pro Jahr wachsen soll.

Wichtige Informationen

24.9%

Wachstumsrate der Gewinne

23.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	42.4%
Wachstumsrate der Einnahmen	8.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	06 Oct 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:HPR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	4,729	884	2,219	2,345	6
12/31/2024	4,213	682	1,906	2,032	7
12/31/2023	3,757	436	1,654	1,134	7
6/30/2023	3,644	438	906	1,041	N/A
3/31/2023	3,576	372	1,002	1,128	N/A
12/31/2022	3,629	521	1,132	1,258	N/A
9/30/2022	3,701	574	1,269	1,370	N/A
6/30/2022	3,813	765	1,269	1,415	N/A
3/31/2022	3,769	862	1,106	1,255	N/A
12/31/2021	3,226	534	907	1,035	N/A
9/30/2021	2,957	552	734	907	N/A
6/30/2021	2,557	518	492	604	N/A
3/31/2021	2,187	280	515	615	N/A
12/31/2020	2,200	390	356	556	N/A
9/30/2020	1,819	792	197	337	N/A
6/30/2020	1,518	517	185	316	N/A
3/31/2020	1,376	592	173	308	N/A
12/31/2019	1,300	573	408	426	N/A
9/30/2019	1,292	82	328	344	N/A
6/30/2019	1,282	97	330	341	N/A
3/31/2019	1,264	77	306	312	N/A
12/31/2018	1,208	-38	178	195	N/A
9/30/2018	1,126	-178	216	229	N/A
6/30/2018	1,073	-275	198	213	N/A
3/31/2018	1,059	-460	183	199	N/A
12/31/2017	1,056	-350	280	284	N/A
9/30/2017	1,092	-495	275	280	N/A
6/30/2017	1,029	-437	335	341	N/A
3/31/2017	997	-212	N/A	340	N/A
12/31/2016	981	-166	N/A	369	N/A
9/30/2016	915	-12	N/A	365	N/A
6/30/2016	933	-3	N/A	325	N/A
3/31/2016	849	14	N/A	319	N/A
12/31/2015	757	40	N/A	194	N/A
9/30/2015	616	-16	N/A	69	N/A
6/30/2015	465	-17	N/A	-18	N/A
3/31/2015	358	-77	N/A	-42	N/A
12/31/2014	297	-264	N/A	28	N/A
9/30/2014	223	-335	N/A	6	N/A
6/30/2014	172	-342	N/A	-5	N/A
3/31/2014	117	-333	N/A	-32	N/A
12/31/2013	74	-149	N/A	-54	N/A
9/30/2013	50	-70	N/A	-60	N/A
6/30/2013	32	-82	N/A	-74	N/A
3/31/2013	25	-86	N/A	-79	N/A
12/31/2012	19	-88	N/A	-77	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HPRDas prognostizierte Gewinnwachstum (24.9% pro Jahr) liegt über der Sparquote (0.4%).

Ertrag vs. Markt: HPRDie Erträge des Unternehmens (24.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (21.1% pro Jahr).

Hohe Wachstumserträge: HPREs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: HPRDie Einnahmen des Unternehmens (8.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (5.6% pro Jahr).

Hohe Wachstumseinnahmen: HPRDie Einnahmen des Unternehmens (8.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von HPR in 3 Jahren voraussichtlich hoch sein wird

Horizon Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Horizon Therapeutics Public Limited Company Revises Earnings Guidance for the Full Year 2022

Horizon Therapeutics Public Limited Company Provides Earnings Guidance for the Full Year 2022

Horizon Therapeutics plc Provides Earnings Guidance for the Full Year 2022

Recent updates

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Horizon Therapeutics Public Limited Company to Report Q2, 2023 Results on Aug 08, 2023

Horizon Therapeutics plc Announces New Analysis of MRI Findings Shows UPLIZNA®? (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People with Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics plc Announces Tepezza® (Teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (Optic-J) in Japan

Horizon Therapeutics plc Announces Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration

Horizon Therapeutics plc Announces the Publication of New Analysis from the N-MOmentum Clinical Trial of UPLIZNA Demonstrating the Utility of A Robust Assay Process

Horizon Therapeutics plc Announces Data from the Teprotumumab Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease

Horizon Therapeutics plc Announces the Publication of New Data from the Phase 3 N-MOmentum Pivotal Trial of UPLIZNA

Horizon Therapeutics plc Announces Presentations At the 2023 Eular European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’S Syndrome

Horizon Therapeutics Public Limited Company to Report Q4, 2022 Results on Mar 01, 2023

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

Amgen Inc. (NasdaqGS:AMGN) entered into a transaction agreement to acquire Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) for $27.1 billion.

Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics

Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Investor sentiment improved over the past week

Insufficient new directors

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (Optic-J) in Japan Evaluating Tepezza® for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Investor sentiment improved over the past week

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Horizon Therapeutics Public Limited Company Announces Data Support the Use of KRYSTEXXA (Pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People with Mild-To-Moderate Chronic Kidney Disease

Third quarter 2022 earnings released: EPS: US$0.59 (vs US$1.44 in 3Q 2021)

Horizon Therapeutics Public Limited Company Revises Earnings Guidance for the Full Year 2022

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Horizon Therapeutics plc Announces New Data from Two Analyses of the Uplizna Phase 3 Pivotal Trial Presented At the 38(Th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Ectrims 2022), Oct. 26-28 in Amsterdam

Horizon Therapeutics Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (Teprotumumab-Trbw) in Adults with Chronic/Low Clinical Activity Score (Cas) Thyroid Eye Disease (Ted)

Horizon Therapeutics plc Announces Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint

Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) announces an Equity Buyback for $500 million worth of its shares.

Second quarter 2022 earnings released: EPS: US$0.27 (vs US$0.70 in 2Q 2021)

Horizon Therapeutics Public Limited Company Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2022

FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

Horizon Therapeutics Public Limited Company to Report Q2, 2022 Results on Aug 03, 2022

Horizon Therapeutics Public Limited Company Announces New Analysis Finds UPLIZNA (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc Submits Regulatory Filing for Uplizna® (Inebilizumab) in Brazil

Horizon Therapeutics Public Limited Company Announces Results of A New Analysis Examining Rates of Hyperglycemia Among Patients Treated with TEPEZZA for TED Compare to Placebo in the Phase 2 and OPTIC Phase 3 Clinical Trials

Horizon Therapeutics plc Announces Analysis from the Phase 3 N-Momentum Study Demonstrates the Effectiveness of Uplizna(R) (Inebilizumab-Cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (Hzn-7734) for the Treatment of Alopecia Areata

First quarter 2022 earnings released: EPS: US$0.89 (vs US$0.55 loss in 1Q 2021)

Horizon Therapeutics Public Limited Company Provides Earnings Guidance for the Full Year 2022

Horizon Therapeutics plc Receives European Commission Approval of Uplizna (Inebilizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

Insufficient new directors

Horizon Therapeutics Public Limited Company to Report Q1, 2022 Results on May 04, 2022

Horizon Therapeutics plc Announces Presentation of A Post-Hoc Analysis from the N-Momentum Phase 3 Pivotal Trial of UPLIZNA

Insider recently sold €3.1m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Horizon Therapeutics plc Provides Earnings Guidance for the Full Year 2022

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

Horizon Therapeutics plc Appoints Sean Clayton Executive Vice President

Horizon Therapeutics Public Limited Company Announces Results from a New Post-Marketing Safety Analysis of Hearing Events Associated with Tepezza for the Treatment of Thyroid Eye Disease

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken